| Literature DB >> 31819304 |
Salem Bajramagic1, Edin Hodzic1, Adi Mulabdic1, Sandin Holjan1, Sajra Vincevic Smajlovic2, Ajdin Rovcanin1.
Abstract
INTRODUCTION: Colorectal Cancer (CRC) is the third most common malignant disease and the fourth most common cause of death associated with malignancy. Adenocarcinomas account for 95% of all cases of colon cancer. Treatment usually includes a surgical resection which is preceded or followed by chemotherapy and radiotherapy depending on the stage. There is constant interest in the microbiological ecosystem of the intestine, which is considered to be crucial for the onset and progression of the disease as well as the development of postoperative complications. Iatrogenic factors associated with the treatment of CRC may result in pronounced expression of virulence of the bacterial intestinal flora and fulminant inflammatory response of the host which ultimately leads to adverse treatment results. The modulation of intestinal microflora by probiotics seems to be an effective method of reducing complications in surgical patients. The question is whether ordering probiotics can lead to more favourable treatment outcomes for our patients who are operated due to colorectal adenocarcinoma, and whether this should become common practice. AIM: To demonstrate the clinical significance of probiotic administration in patients treated for colorectal adenocarcinoma and the results compared with relevant studies. PATIENTS AND METHODS: In a randomized controlled prospective study conducted at the Clinic of General and Abdominal Surgery of the UCCS in the period of 01 January 2017 until 31 December 2017, there were a total of 78 patients with colorectal adenocarcinoma. Patients were divided into two groups: a group treated with oral probiotics (n = 39) according to the 2x1 scheme starting from the third postoperative day lasting for the next thirty days, followed by 1x1 lasting for two weeks in each subsequent month to one year, and the control group (n = 39) which was not routinely treated with probiotics.Entities:
Keywords: colon surgery; colorectal cancer; probiotics; surgical complications
Mesh:
Year: 2019 PMID: 31819304 PMCID: PMC6885229 DOI: 10.5455/medarh.2019.73.316-320
Source DB: PubMed Journal: Med Arch ISSN: 0350-199X
Final outcome of treatment in relation to the use of probiotics. χ=1.013; p=0.500
| Patients treated with probiotics | Patients which were not treated withprobiotics | Total | ||
|---|---|---|---|---|
| Treatment outcome | Discharged | 39 (100.0%) | 38 (97.4%) | 77 (98.7%) |
| Mortal outcome | 0 (0.0%) | 1 (2.6%) | 1 (1.3%) | |
| Total | 39 (50,0%) | 39 (50.0%) | 78 (100,0%) |
Frequency of postoperative complications in relation to probiotic treatment
| Patients treated with probiotics | Patients which were not treated withprobiotics | Total | ||
|---|---|---|---|---|
| Postoperative complications | SSI | |||
| Anastomosis loosening | ||||
| Ileus | ||||
| Intraabdominal abscess |
Multivariate regression analysis of complications in relation to ordinary probiotics
| Variables in equation | ||||||
|---|---|---|---|---|---|---|
| OR | S.E. | Wald | df | Sig. | 95% CI | |
| SSI | 1.425 | .488 | .528 | 1 | .467 | -1.245-5.412 |
| Anastomosis loosening | 1.001 | .870 | 1.324 | 1 | .250 | 1.586-3.241 |
| Ileus | 2.430 | 1.082 | 5.059 | 1 | .025 | 1.854-2.985 |
| Intraabdominal abscess | 0.487 | .635 | .391 | 1 | .532 | -0.254-4.258 |